CYDY - CytoDyn: Managing My Position Following BLA Submission And COVID-19 Progress
April 27th was a big day for CytoDyn (CYDY) investors due to the company finally announcing they have submitted the final portion of their BLA to the FDA for leronlimab as a combination therapy with HAART for HIV. What is more, the company publicized leronlimab's branded name, Vyrologix, which has a "conditional acceptance" by the FDA and the company was also notified that they have a notice of allowance from the U.S. Trademark Office for Vyrologix. Furthermore, the company hosted a conference call that discussed the company's next steps including finishing their once-weekly